Thyroid Eye Disease
Thyroid Eye Disease 360˚ Guidance: Pathogenesis, Differential Diagnosis, and Medical Trends
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Q&A: What PCPs need to know about thyroid eye disease
Primary care providers can play an important role in the management of an often-overlooked disorder, thyroid eye disease, according to an expert.
Hearing loss with teprotumumab more likely for adults with baseline hearing dysfunction
Hearing loss occurred more frequently among adults who received teprotumumab for the treatment of thyroid eye disease if they had impaired hearing at the start of therapy, according to a research letter published in Thyroid.
Comanagement of Thyroid Eye Disease for the Ophthalmology and Optometry Provider
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Comanagement of Thyroid Disorders for the Endocrinology Provider
This activity is supported by and educational grant from Horizon Therapeutics USA, Inc.
VIDEO: Check for mimics of thyroid eye disease
WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Andrew G. Lee, MD, discusses neuro-ophthalmic mimics of thyroid eye disease.
Thyroid Eye Disease 360˚: A Podcast Series
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Thyroid Eye Disease: Insights Into Practical Management Approaches
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
Will teprotumumab supplant traditional options in the treatment of thyroid eye disease?
Teprotumumab has marked the dawn of a new era in the treatment of thyroid eye disease.
Treatment for thyroid eye disease enters new era, shows potential for brighter future
Until recently, patients with active thyroid eye disease had limited options for treatment of their condition besides observation.